Core Viewpoint - The stock price of Color Star Technology (0869.HK) dropped over 15% to HKD 0.43, marking a new low since April 2023, following the announcement that the long-standing licensing agreement for the "Teenage Mutant Ninja Turtles" will not be renewed after 2027 [1] Group 1: Financial Impact - The "Teenage Mutant Ninja Turtles" products were a significant revenue source for the company, with sales revenue from these products increasing from 8% of total revenue in 2021 to 77% in 2022 [1] - The sales revenue contribution from "Teenage Mutant Ninja Turtles" products is projected to decline to 47% by December 31, 2024, and further to 36% by June 30, 2025 [1]

彩星玩具(00869)发布公告，根据 Viacom Media Networks 作为特许权授予人("特许权授予人")与集团全 资附属公司彩星玩具国际有限公司("PICL")作为特许权被授权人签订的现行特许权协议("特许权协 议")，PICL 获授予设计、制造、分销及销售"忍者龟"产品("特许权产品")的权利。自2025年10月起，双 方一直就特许权协议续期进行磋商，惟 PICL 最近已接获特许权授予人的正式通知，特许权协议于2026 年12月31日届满后将不获续期。因此，PICL 销售特许权产品的权利将于2026年12月31日终止，而根据 特许权协议，PICL 处置特许权产品存货的权利将于其届满后九十天终止。 于特许权协议届满后，集团将在适当情况下继续寻找及评估符合其策略考量的潜在特许权机会，并持续 致力于开发及管理现有的产品系列，包括但不限于"Power Rangers"、"MonsterVerse"及"Winx"。 根据本公司资料，特许权产品销售收入分别约占截至2021年12月31日、2022年12月31日、2023年12月31 日、2024年12月31日止年度及截至2025年6月30日止六个月的集团综 ...

格隆汇12月23日丨彩星集团(00635.HK)公布，承彩星玩具(00869.HK)公布所，根据 Viacom Media Networks 作为特许权授予人("特许权授予人")与彩星玩具(00869.HK)集团全资附属公司彩星玩具国际有 限公司("PICL")作为特许权被授权人签订之现行特许权协议，PICL 获授予设计、制造、分销及销售 「忍者龟」产品("特许权产品")的权利。自2025年10月起，双方一直就特许权协议续期进行磋商，惟 PICL 最近已接获特许权授予人的正式通知，特许权协议于2026年12月31日届满后将不获续期。因此， PICL 销售特许权产品之权利将于2026年12月31日终止，而根据特许权协议，PICL 处置特许权产品存货 的权利将于其届满后九十天终止。 由于彩星玩具为公司主要附属公司，预期上述发展将对本集团之综合财务表现产生相应影响。根据本集 团之资料，特许权产品销售收入分别约占集团于截至2021年12月31日、2022年12月31日、2023年12月31 日、2024年12月31日止年度及截至2025年6月30日止六个月的综合收入约6%、9%、67%、40%及26%。 根据彩星玩具 ...

Core Viewpoint - The company, 彩星玩具, will lose its rights to sell "Ninja Turtles" products after December 31, 2026, as the current licensing agreement will not be renewed [1] Group 1: Licensing Agreement Details - 彩星玩具's subsidiary, 彩星玩具国际有限公司 (PICL), has been granted rights to design, manufacture, distribute, and sell "Ninja Turtles" products under a licensing agreement with Viacom Media Networks [1] - Negotiations for the renewal of the licensing agreement have been ongoing since October 2025, but PICL has received formal notification that the agreement will expire on December 31, 2026, without renewal [1] - The rights to dispose of inventory related to the licensed products will terminate 90 days after the agreement's expiration [1] Group 2: Financial Impact - Sales revenue from licensed products accounted for approximately 8%, 13%, 77%, 47%, and 36% of the company's consolidated revenue for the years ending December 31, 2021, December 31, 2022, December 31, 2023, December 31, 2024, and the six months ending June 30, 2025, respectively [1] Group 3: Future Opportunities - Following the expiration of the licensing agreement, the company will continue to seek and evaluate potential licensing opportunities that align with its strategic considerations [2] - The company remains committed to developing and managing its existing product lines, including "Power Rangers," "MonsterVerse," and "Winx" [2]

本公佈乃彩星玩具有限公司（「本公司」，連同其附屬公司為「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09(2)(a)條及香港法例 第 571 章證券及期貨條例第 XIVA 部之內幕消息條文（如上市規則所定義）而刊 發。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者有關 本集團最新業務發展。 根據 Viacom Media Networks 作為特許權授予人（「特許權授予人」）與本集團全 資附屬公司彩星玩具國際有限公司（「PICL」）作為特許權被授權人簽訂之現行 特許權協議（「特許權協議」），PICL 獲授予設計、製造、分銷及銷售「 忍者龜 」 產品（「特許權產品」）之權利。自二零二五年十月起，雙方一直就特許權協議續 期進行磋商，惟 PICL 最近已接獲特許權授予人的正式通知，特許權協議於二零二 六年十二月三十一日屆滿後將不獲續期。因此，PICL 銷售特許權產品之權利將於二 零二六年十二月三十一日終止，而根據特許權協議，PICL 處置特許權產品存貨之權 利將於其屆滿後九十天終止。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 ...

Core Viewpoint - 彩星玩具 announced a series of lease agreements for properties in Hong Kong and the UK, effective January 1, 2026, through its indirect wholly-owned subsidiary PICL [1] Group 1: Lease Agreements - The company will continue leasing properties for office, warehouse, and exhibition purposes under the same terms as current leases [1] - The first lease agreement involves PPML acting as an agent for Belmont Limited, covering a property in Hong Kong [1] - The second lease agreement also involves PPML, this time acting as an agent for Bagnols Limited, for another property in Hong Kong [1] - A third lease agreement is established with GWL as the owner for a property in the UK [1] Group 2: Shareholding Structure - PHL indirectly owns and controls approximately 50.85% of the company's shareholding, making it the major shareholder [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 PLAYAMTES TOYS LIMITED 彩星玩具有限公司＊ ( 於百慕達註冊成立之有限公司 ) (股份代號：869) 關連交易 租約續期 茲提述現行租約，據此，關連業主同意向本集團出租若干物業以作辦公室及倉庫之 用。現行租約將於二零二五年十二月三十一日屆滿。 董事會宣佈，於二零二五年十二月五日，本公司之間接全資附屬公司PICL作為租戶 與下方訂立該等租約，繼續向關連業主租賃以根據現行租約相同物業作辦公室、倉 庫及展覽用途： PHL間接擁有並控制本公司約50.85%之股份權益，為本公司之主要股東。因此，根 據上市規則，PPML、GWL、Belmont Limited及Bagnols Limited均為PHL之聯繋人， 因而為本公司之關連人士。 根據香港財務報告準則第16號「租賃」，本集團將於其綜合財務狀況表内將該等租 約租金總額之現值確認為使用權資產，估計價值約為港幣14,200,000元。因此，就 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 彩星玩具有限公司 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00869 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,180,000,000 | | 0 | | 1,180,000,000 | | 增加 / 減少 (-) | | | 0 | | | | | | 本月底結存 | | | 1,180,000,000 | | 0 | | 1,180,000,000 | 第 2 頁 共 10 頁 v 1.1.1 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 彩星玩具有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00869 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.01 | HKD | | 30,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.01 | HKD | | 30,000,000 | 本月底法定/註冊股本總額： HKD 30,000,000 F ...

Group 1 - The core issue is that 康泰医学 received a warning letter from the FDA on October 2, 2025, due to non-compliance with medical device quality system regulations during an inspection conducted from June 9 to June 12, 2025 [2] - The warning letter indicates that 康泰医学's medical devices exported to the U.S. did not meet the requirements of the U.S. federal regulations 21 CFR Part 820, which may lead to the rejection of its products until the issues are resolved [2] - 康泰医学 plans to submit a response report to the FDA detailing corrective actions and timelines, aiming to resolve the issues and lift the warning [2] Group 2 - In 2024, 康泰医学 generated sales revenue of 114 million yuan from the U.S., accounting for 23.84% of its total revenue, while in the first half of 2025, sales revenue from the U.S. was 41.89 million yuan, representing 19.26% of total revenue [2] - The company has a high export ratio, with 73.08% of its sales coming from international markets in 2024, indicating potential broader impacts from the FDA's judgment on sales in other countries [3] - As of September 16, 2025, the second-largest shareholder, 王桂丽, reduced her stake in 康泰医学 to 10% from 14.7% since 2021, indicating a significant decrease in ownership [3] Group 3 - On October 10, 康泰医学's stock closed at 16.4 yuan per share, with a market capitalization of 6.59 billion yuan [4]